☆ 4.7 Article

A phase II randomized, double-blind, parallel group, 26-week study of GSK-3 inhibitor tideglusib in Alzheimer's disease (ARGO trial)

Alzheimers & Dementia (2013)

Get Full Text
Add to Collection

Journal

Alzheimers & Dementia
Volume 9, Issue 4, Pages P689-P690

Publisher

Elsevier BV
DOI: 10.1016/j.jalz.2013.04.359

Keywords

-

Categories

Clinical Neurology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.